Summary Slide.png (132.78 kB)

Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study

media

posted on 2021-02-17, 10:56 authored by Adis journals on behalf of, Yoshinori Umezawa, Shinya Sakurai, Naoki Hoshii, Hidemi Nakagawa

Article full text

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

References

https://link.springer.com/article/10.1007/s13555-021-00494-z

Usage metrics

Read the peer-reviewed publication

Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study

Dermatology and Therapy

Keywords

Certolizumab pegol Japan Plaque psoriasis Tumor necrosis factor-alpha

Licence

CC BY-NC 4.0

Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports